Pavan Vaddady
Overview
Explore the profile of Pavan Vaddady including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
24
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vaddady P, Glatard A, Smania G, Nakayama S, Inoue H, Kurumaddali A, et al.
Clin Transl Sci
. 2024 Nov;
17(12):e70074.
PMID: 39601658
The population pharmacokinetics (PK) of quizartinib and its pharmacologically active metabolite AC886 have been previously described in healthy volunteers (HV) and relapsed/refractory (R/R) FLT3-internal-tandem-duplication-positive (FLT3-IDT-positive) acute myeloid leukemia (AML) patients...
2.
Vaddady P, Smania G, Nakayama S, Inoue H, Kurumaddali A, AbuTarif M, et al.
Clin Transl Sci
. 2024 Nov;
17(11):e70065.
PMID: 39533519
Quizartinib prolongs QT interval through inhibition of the slow delayed rectifier potassium current (I). We used non-linear mixed-effects modeling to explore the relationship between quizartinib and its pharmacologically active metabolite...
3.
Davis C, Vaddady P
CPT Pharmacometrics Syst Pharmacol
. 2024 Oct;
14(1):52-67.
PMID: 39465998
Stan is a powerful probabilistic programming language designed mainly for Bayesian data analysis. Torsten is a collection of Stan functions that handles the events (e.g., dosing events) and solves the...
4.
Samineni D, Venkatakrishnan K, Othman A, Pithavala Y, Poondru S, Patel C, et al.
Clin Pharmacol Ther
. 2024 May;
116(3):531-545.
PMID: 38752712
The landscape of oncology drug development has witnessed remarkable advancements over the last few decades, significantly improving clinical outcomes and quality of life for patients with cancer. Project Optimus, introduced...
5.
Lu Y, Liang S, Hong Y, Tajima N, Patel K, Li H, et al.
CPT Pharmacometrics Syst Pharmacol
. 2023 Nov;
13(1):23-28.
PMID: 37915242
To replace the conventional maximum tolerated dose (MTD) approach, a paradigm for dose optimization and dose selection that relies on model-informed drug development (MIDD) approaches has been proposed in oncology....
6.
Terranova N, Renard D, Shahin M, Menon S, Cao Y, Hop C, et al.
Clin Pharmacol Ther
. 2023 Sep;
115(4):658-672.
PMID: 37716910
Recent breakthroughs in artificial intelligence (AI) and machine learning (ML) have ushered in a new era of possibilities across various scientific domains. One area where these advancements hold significant promise...
7.
Bradley J, Makieieva N, Tondel C, Roilides E, Kelly M, Patel M, et al.
J Clin Pharmacol
. 2023 Aug;
63(12):1387-1397.
PMID: 37562063
Imipenem/cilastatin/relebactam is approved for the treatment of serious gram-negative bacterial infections in adults. This study assessed the pharmacokinetics (PK), safety, and tolerability of a single dose of imipenem/cilastatin/relebactam (with a...
8.
Walford G, Duncan K, Hernandez M, Vaddady P, Hompesch M, Morrow L, et al.
Clin Pharmacol Ther
. 2022 Apr;
112(1):125-132.
PMID: 35390172
Insulin molecules of size much greater than natural insulin have been synthesized and studied with the intention of widening the therapeutic window between adequate glycemic control and hypoglycemia as compared...
9.
Sun L, Xu Y, Dube N, Anderson M, Breidinger S, Vaddady P, et al.
J Pharm Biomed Anal
. 2022 Feb;
212:114639.
PMID: 35176654
For pharmacokinetics characterization of a therapeutic insulin dimer, an ultrasensitive plasma method was required due to the expected low circulating levels in humans. A bioanalytical strategy combining immunoprecipitation enrichment with...
10.
Vaddady P, Kandala B
CPT Pharmacometrics Syst Pharmacol
. 2021 Jul;
10(11):1323-1331.
PMID: 34319009
ModVizPop is an interactive and dynamic visualization tool developed for simulating differential equation-based population pharmacokinetic (PK) and pharmacodynamic (PD) models with variability. It has a built-in PK/PD ordinary differential equations...